e-learning
resources
Virtual 2020
Pre-Congress Content
Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
IgG4 as a potential biomarker of acute exacerbations in ILD
S. Torrisi (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), V. Somogyi (Heidelberg, Germany), M. Polke (Heidelberg, Germany), L. Kehler (Heidelberg, Germany), J. Gauldie (Hamilton, Canada), M. Kreuter (Heidelberg, Germany)
Source:
Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Session:
Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Session type:
E-poster session
Number:
729
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Torrisi (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), V. Somogyi (Heidelberg, Germany), M. Polke (Heidelberg, Germany), L. Kehler (Heidelberg, Germany), J. Gauldie (Hamilton, Canada), M. Kreuter (Heidelberg, Germany). IgG4 as a potential biomarker of acute exacerbations in ILD. 729
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
HISTOLOGICAL FINDINGS IN TRANSBRONCHIAL CRYOBIOPSIES OBTAINED FROM PATIENTS AFTER COVID-19
Does “UIPAF” really exist?
Diagnosis and management of chronic fibrotic hypersensitivity pneumonitis
Related content which might interest you:
The prognostic value of cardiac and inflammatory biomarkers in acute exacerbations of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Proteinase-3 as a biomarker of exacerbations in bronchiectasis.
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Procalcitonin use in acute exacerbations of COPD
Source: Annual Congress 2011 - COPD exacerbation
Year: 2011
Increased serum endotoxin levels as biomarker in acute exacerbations of COPD.
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
The value of inflammation markers in acute infective exacerbations of bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 217s
Year: 2001
The role of biomarkers in predicting outcomes in acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
Source: Annual Congress 2013 –Infection, sepsis and outcomes in ICU
Year: 2013
Clinical implications of serum procalcitonin in acute exacerbations of chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Clinical value of C-reactive protein in severe acute exacerbations of COPD
Source: Annual Congress 2005 - COPD - acute exacerbations
Year: 2005
Clinical and exacerbation characteristics may predict treatment response in acute exacerbations of COPD
Source: International Congress 2018 – COPD exacerbations and bronchiectasis
Year: 2018
Combined serum eosinophil count and procalcitonin level as a marker of bacterial infection in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Temporal profile and clinical utility of inflammatory markers in patients with acute exacerbation of COPD
Source: Annual Congress 2008 - Structural remodelling in COPD
Year: 2008
The assesment of serum TNFα levels in COPD acute exacerbation and the effects of inhaler steroids on clinical and inflammatory determinants
Source: Eur Respir J 2002; 20: Suppl. 38, 312s
Year: 2002
Lung and serum biomarkers of tissue lesions due to acute exacerbation of COPD
Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Year: 2012
Copeptin – a marker for differential diagnosis between acute exacerbation of COPD and heart failure in patients with acute dyspnea
Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases
Year: 2021
Predictive value of multiorgan imaging biomarkers for predicting exacerbations in COPD patients
Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Year: 2018
Serum periostin in patients hospitalized for COPD exacerbations
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
Plasma biomarkers and response to therapy at exacerbation of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 39s
Year: 2007
BNP level in patients with COPD exacerbations
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
The relationship of sinusitis with acute exacerbations of COPD and acute asthmatic attack
Source: Eur Respir J 2003; 22: Suppl. 45, 239s
Year: 2003
Serum SP-A and SP-D levels in patients admitted to the hospital with acute COPD exacerbation
Source: International Congress 2016 – Inflammatory biomarkers in airway diseases
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept